<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1180">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389698</url>
  </required_header>
  <id_info>
    <org_study_id>17-01336</org_study_id>
    <nct_id>NCT03389698</nct_id>
  </id_info>
  <brief_title>Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD</brief_title>
  <official_title>Developing Advanced Blood-Brain Barrier Permeability Imaging for Early Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aging is the primary risk factor in aging-related dementia. An important initiating factor&#xD;
      for the development and progression of cognitive impairment is disruption of the blood-brain&#xD;
      barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and&#xD;
      protecting neural tissues from toxins. It is hypothesized that such changes known to be&#xD;
      common in aging and can be an early process that precedes Alzheimer's Disease (AD). The&#xD;
      microvascular changes related to subtle BBB disruption can be measured with&#xD;
      permeability-surface area (PS) derived from GRASP DCE-MRI acquired less than 10 minutes, and&#xD;
      the patterns of increased PS in normal and abnormal aging are different.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Permeability Surface Area (PS) estimates derived from 9 min GRASP DCE reconstruction</measure>
    <time_frame>9 Minutes</time_frame>
    <description>to determine if are in permability surface area for GRADP measure is consistent with the estimates from the full 21 min data set</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Heatlthy Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cognitively normal (CN) subjects in two age groups: young(20-40) and old (65-85)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amnestic mild cognitive impairment (aMCI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 participants who have aMCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GRASP DCE-MRI</intervention_name>
    <description>DCE-MRI termed Golden-angle Radial Sparse Parallel (GRASP) significantly improves both spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.</description>
    <arm_group_label>Amnestic mild cognitive impairment (aMCI)</arm_group_label>
    <arm_group_label>Heatlthy Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3T Brain Scan</intervention_name>
    <description>up to 60 minutes: 3T brain scan, a portion of which uses the GRASP DCE-MRI sequence (the first 21 minutes of the scan for CN cohorts and the first 9 minutes of the scan for the Amnestic Mild Cognitive Impairment cohort)</description>
    <arm_group_label>Amnestic mild cognitive impairment (aMCI)</arm_group_label>
    <arm_group_label>Heatlthy Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects that have been diagnosed with aMCI ages 65-85&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, planning to get pregnant, or nursing.&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  Intracranial clips, metal implants, unremovable jewelries, metal in eyes.&#xD;
&#xD;
          -  History or presence of any other major medical, neurologic or psychiatric conditions,&#xD;
             such as Alzheimer's diseases, Parkinson's diseases, and stroke.&#xD;
&#xD;
          -  Renal or liver disease as this may cause concerns related to Gad-based contrast agent&#xD;
&#xD;
          -  Allergy to the contrast agent Gadolinium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yulin Ge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Morton</last_name>
    <phone>212-263-7541</phone>
    <email>Charles.Morton@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danielle Costanzo</last_name>
    <phone>212 263 0380</phone>
    <email>Danielle.Costanzo@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Morton</last_name>
      <email>Charles.morton@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Yulin Ge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>August 11, 2022</last_update_submitted>
  <last_update_submitted_qc>August 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

